preDiCT

Many drugs fail to reach the market because of side effects on the heart. The principal objective of this proposal is to create an advanced computational technology for in silico assessment of the efficacy and safety of specific drugs [ICT-2007.5.3(c) (3)], i.e. an open environment comprising validated computational models, tools and numerical methods that will enable simulations of drug actions on the electrophysiology of the human heart.

Such simulations will involve modelling of drug interactions at the molecular and cellular level, will extend current technology to enable prediction of the effects of those interactions on the dynamics of the whole heart, and will lead to an understanding of how genetic factors can be used to assess patient-specific risk profiles. This requires a multi-level systems approach, based on multi-scale, multi-physics methods, including computations on adaptive spatial grids and multi-grid time integration. Computations on realistic models at appropriate spatial and temporal scales are currently not feasible, so we will investigate new algorithms and their implementation on high-performance platforms, including a new generation of petaflop computers, to achieve 'faster than real-time' simulation.

These tools form part of the infrastructure required to simulate the physiology of major organ systems, thereby contributing to the goal of creating the Virtual Physiological Human (VPH) [ICT-2007.5.3]. The balanced team in this project, including founders of the Human Physiome Project, has decades of experience in the experimental study and modelling of the electrophysiology and mechanics of the heart, while pharmaceutical industry partners bring deep understanding of the mechanisms of drug actions. The results will demonstrate the value of the VPH initiative to fundamental scientific understanding of the heart, with major economic and clinical impacts through accelerated drug development, approval and use.

For further information, please visit:
http://www.vph-predict.eu

Project co-ordinator:
The Chancellor, Master and Scholars of the University of Oxford

Partners:

  • F. Hoffmann-La Roche AG
  • Szegedi Tudományegyetem
  • Fujitsu Laboratories of Europe Limited
  • Glaxo Smithkline Research and Development
  • Universidad Politécnica de Valencia
  • Centro di Ricerca, Sviluppo e Studi Superiori in Sardegna
  • Novartis Pharma AG
  • Aureus Pharma SA

Timetable: from 06/2008 – to 05/2011

Total cost: € 5.545.692

EC funding: € 4.100.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

mHealth as Effective as Clinic-Based Int…

A mobile health (mHealth) intervention was found to be as effective as a clinic-based group intervention for people with serious mental illness in a new study published online in Psychiatric...

Mobile Health Technology can Potentially…

Mobile health technology has the potential to transform the way we prevent and manage heart disease, but there are unanswered questions about how to optimize this technology and maintain engagement...

New Computational Tool could Help Optimi…

Scientists have developed a novel computational approach that incorporates individual patients' brain activity to calculate optimal, personalized brain stimulation treatment for Alzheimer's disease. Lazaro Sanchez-Rodriguez of the University of Calgary...

First Call for Science and Technology at…

Participate in the first ever ESC Digital Health Call for Technology, for the chance to present your innovations, your technology or your products at ESC Congress 2018 in front of...

Siemens Healthineers Assists Swiss Post …

To expand its portfolio in the area of eHealth, Swiss Post will make use of the Siemens Healthineers eHealth Solutions(1) in the future. The eHealth solution offered by Swiss Post...

Philips Expands its Therapeutic Care Bus…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced that it has acquired Remote Diagnostic Technologies (RDT), a UK-based leading innovator of advanced solutions for the...

Joined-Up Health & Care Conference M…

InterSystems, a global leader in health information technology, will be celebrating a double anniversary at its annual Joined-Up Health & Care conference. This year’s event at The Belfry, Sutton Coldfield...

Ingestible 'Bacteria on a Chip' could He…

MIT researchers have built an ingestible sensor equipped with genetically engineered bacteria that can diagnose bleeding in the stomach or other gastrointestinal problems. This "bacteria-on-a-chip" approach combines sensors made from...

FDA Takes New Steps to Advance Digital H…

Today, the FDA is opening a docket to solicit feedback on important provisions of the 21st Century Cures Act ("Cures Act"). The Cures Act amended the Federal Food, Drug, and...

Mobile App for Autism Screening Yields U…

A Duke study of an iPhone app to screen young children for signs of autism has found that the app is easy to use, welcomed by caregivers and good at...

Open Call MSCA-IF-2018: Individual Fello…

The goal of the Individual Fellowships is to enhance the creative and innovative potential of experienced researchers, wishing to diversify their individual competence in terms of skill acquisition through advanced...

Lexmark Partners with NHS Shared Busines…

Lexmark, a global imaging solutions leader, today announced a partnership with NHS Shared Business Services (NHS SBS) to enable the public sector to utilise Lexmark technology to support their aim...